The ESMO Asia Cancer Conference 2025 is an important annual scientific event for the Asia-Pacific region.
Asia currently records nearly half of new cases and more than half of deaths from cancer worldwide. In Vietnam, the number of new cancer cases is forecast to increase by 23% by 2030, of which lung, liver and breast cancer accounts for a high proportion.
For lung cancer alone, 75% of cases are detected late, causing a 5-year survival rate of only 14.8%, showing the need to increase screening and early treatment.
At the conference, AstraZeneca introduced 37 reports and 10 clinical studies with many pioneering results. The research focuses on EGFR resistance in lung cancer, targeted therapy for HR+/HER2- breast cancer, and immunoptimulation, ADC in the group of gastrointestinal cancers.
In parallel with scientific data, AstraZeneca has implemented many initiatives in Asia and Vietnam such as expanding screening, biomarker testing and applying AI in diagnosis, aiming to improve the effectiveness of cancer care in the region.
